Related Experiment Video
Updated: Jan 7, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Adjuvant Chemotherapy in Retinoblastoma with Postlaminar Optic Nerve Invasion: A Global Multicenter Study
Michelle Lin1, Sarah B Pike1, Mark W Reid2
1The Vision Center, Children's Hospital Los Angeles, Los Angeles, California; USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.
Purpose:
To evaluate outcomes of patients with retinoblastoma (RB) who underwent primary enucleation with histopathologic evidence of postlaminar optic nerve invasion (PLONI), comparing those who received adjuvant chemotherapy to those who did not.
Design:
Multicenter retrospective cohort study.
Participants:
A total of 292 patients across 9 countries with RB and histopathologic evidence of PLONI after primary enucleation.
Methods:
Patients who received adjuvant chemotherapy (n = 276) were compared with those who did not (n = 16) using Fisher exact tests, Welch t tests, and proportional hazard models (Cox and competing risks). Subanalyses were performed for PLONI and massive choroidal invasion and isolated PLONI.
Main Outcome Measures:
Orbital tumor recurrence, metastasis, and death.
Results:
Patients who did not receive adjuvant chemotherapy had higher rates of orbital tumor recurrence (31% vs 2%, P < 0.001), metastasis (31% vs 6%, P = 0.001), and death (38% vs 9%, P = 0.007). In time-to-event analyses, patients who did not receive adjuvant chemotherapy experienced greater hazard of orbital tumor recurrence (subhazard ratio [SHR] = 19.31, 95% confidence interval [CI]: 5.56-67.05), metastasis (SHR = 5.39, 95% CI: 1.75-16.60), and death (hazard ratio = 4.74, 95% CI: 1.75-12.81). Outcomes were similar among patients with PLONI and massive choroidal invasion. Among patients with isolated PLONI, those who did not receive adjuvant chemotherapy showed significantly greater hazard of metastasis over time than those who received adjuvant chemotherapy (SHR = 40.68, 95% CI: 9.65-171.55, P < 0.001). All patients with metastasis or orbital tumor recurrence eventually died during follow-up (mean duration: 75.3 months).
Conclusions:
In patients with RB and PLONI with additional high-risk histopathologic features, initiating adjuvant chemotherapy after primary enucleation significantly reduced rates of orbital tumor recurrence, metastasis, and death. Although patients with isolated PLONI experienced fewer events and had a lower metastatic risk compared with those with multiple histopathologic features, adjuvant chemotherapy still reduced metastatic risk over time.
Financial Disclosure(S):
The authors have no proprietary or commercial interest in any materials discussed in this article.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:28Angle Closure Glaucoma: Treatment
02:56Treatment Resistant Cancers
01:25Glaucoma: Overview